[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588501":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":42,"responsibleParty":60,"collaborators":25,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"telemedicine guided care group","EXPERIMENTAL","Patients will be instructed to response to questions using the App daily. The parameters and questionnaires will be evaluated by the Telemedicine team, and participants will be contacted via phone 1 week after discharge and subsequently every 7-10 days to discuss the up-titration of the HF medications.",[13],"Other: guideline-directed medical therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"usual care group","ACTIVE_COMPARATOR","usual care according to local practice",[19],"Other: usual care",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"usual care","Patients in the \"usual care group\" will be followed up according to the local practice until the end of the study.",[15],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"guideline-directed medical therapy","Patients are followed via an App, data will be evaluated by the Telemedicine team, and participants will be contacted via phone 1 week after discharge and subsequently every 7-10 days to discuss the up-titration of the HF medications.",[9],[31],"telemedicine",[33],{"name":34,"affiliation":35,"role":36},"Qian Zhou, Prof. MD","Universitätsspital Basel","PRINCIPAL_INVESTIGATOR",[38],{"name":34,"role":39,"phone":40,"phoneExt":25,"email":41},"CONTACT","+41 3286828","qian.zhou@usb.ch",[43],{"facility":44,"status":45,"city":46,"state":25,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":51,"coordinates":52},"Point",[53,54],7.57327,47.55839,{"lat":54,"lon":53},[57,59],{"name":58,"role":39,"phone":40,"phoneExt":25,"email":41},"Qian Zhou, Prof. MD.",{"name":58,"role":36,"phone":25,"phoneExt":25,"email":25},{"type":61,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100588501","digital-solutions-in-heart-therapy-dignity-100588501",false,"NCT06942221","Digital Solutions in Heart Therapy (DIGNITY)","Digital Solutions in Heart Therapy (DIGNITY) - a Randomized Controlled Trial Using Telemedicine for Heart Failure Treatment","DIGNITY - HF","Inclusion Criteria:\n\n1. Age \\> 18 years at the time of hospital admission\n2. Ability to use a (smart)phone and\u002For tablet for the follow-up\n3. Documented left ventricular ejection fraction (LVEF) \\> 40% assessed within preceding 12 months\n4. Not treated with optimal doses of oral HF therapies within 2 days before anticipated hospital discharge for acute HF in at least one of the medication categories (for details see Table 1 on page 10)\n5. Hospitalized due to acute HF decompensation.\n6. Specific measures within 24 hours prior to randomization\n\n   * Systolic blood pressure \\> 100 mmHg, and heart rate \\> 60bpm\n   * Serum potassium \\\u003C 5mmol\u002FL\n\nExclusion Criteria:\n\n1. Inability to use a (smart)phone or tablet\n2. Clear intolerance to high doses of betablockers, ACE inhibitors, or ARBs\n3. Estimated glomerular filtration rate \\\u003C30ml\u002Fmin\u002F1.73m2 or dialysis\n4. Myocardial infarction, unstable angina or cardiac surgery within 3 months, percutaneous transluminal coronary intervention within 1 months prior to screening\n5. Cardiac resynchronization therapy device implantation within 3 months prior to screening\n6. Presence of significant obstructive lesion of the left ventricular outflow tract\n7. Amyloid cardiomyopathy\n8. Participation in other clinical trials for drugs\n9. Pregnant or nursing women\n10. Women of child-bearing potential who are unwilling to abstain from sexual intercourse with men or practice appropriate contraception","ALL","18 Years",{"count":73,"type":74},140,"ESTIMATED","INTERVENTIONAL",[77],"NA","This study aims to assess the safety and effectiveness of telemedicine guided strategy on guideline-directed medical therapy (GDMT) optimization in hospitalized patients with heart failure in comparison to usual care in Switzerland.",[80],"Heart Failure With Reduced Ejection Fraction",[27,31],"2025-12-01",{"date":84,"type":85},"2025-12-02","ACTUAL",{"date":87,"type":85},"2025-07-17",{"date":89,"type":74},"2026-12-31",{"name":5,"class":6},1]